The landscape of digital health and diabetes management reached a significant milestone on October 28, when Glooko, Inc., a prominent global player in glycemic safety and digital health solutions, unveiled new real-world data at the Diabetes Technology Society (DTS) meeting. The presentation focused on the clinical efficacy of EndoTool IV, a sophisticated computerized intravenous insulin dosing application, specifically within the high-stakes environment of labor and delivery (L&D). As the medical community increasingly looks toward automated and personalized titration tools to improve patient safety, this data provides a critical look at how technology can bridge the gap between complex physiological needs and clinical execution during one of the most dynamic periods of a patient’s healthcare journey.
The poster presentation, titled “Use of a Computerized Intravenous Insulin Dosing Application in Pregnancy,” detailed a retrospective analysis of outcomes for pregnant individuals who required intravenous insulin during the intrapartum period. This phase of care is notoriously difficult for endocrinologists and obstetricians alike, as the body undergoes rapid hormonal shifts that can cause glucose levels to fluctuate wildly. The primary challenge for care teams is to maintain a narrow glycemic window—managing hyperglycemia to protect the neonate while simultaneously ensuring that the mother does not descend into hypoglycemia, which can be life-threatening during the physical stress of labor.
The Scope and Methodology of the Retrospective Analysis
The findings presented at the DTS meeting were derived from a comprehensive review of the 2025 EndoTool IV database. This dataset is particularly robust, encompassing 267 individuals treated across 43 different healthcare facilities. By pulling data from a wide variety of clinical settings, the study offers a realistic cross-section of how the technology performs in diverse hospital environments, rather than in a controlled clinical trial setting.
Researchers categorized the participants into two primary groups to compare the effectiveness of the tool across different underlying conditions: those with type 1 diabetes and those with either gestational diabetes mellitus (GDM) or type 2 diabetes. This distinction is vital because the insulin sensitivity and requirements of a patient with type 1 diabetes differ significantly from those with GDM or type 2 diabetes, especially when the body is under the metabolic stress of labor.
The analysis focused on several key performance indicators, including the ability of the EndoTool IV algorithm to reach and maintain target glucose ranges and the incidence of adverse glycemic events. The results indicated that the personalized nature of the algorithm allowed for precise adjustments that catered to the individual’s shifting insulin needs in real-time, a task that is often labor-intensive and prone to human error when performed manually by nursing staff.
The Clinical Challenges of Labor and Delivery
To understand the significance of the Glooko data, one must consider the physiological complexity of pregnancy and birth. During pregnancy, insulin resistance typically increases due to placental hormones. However, during the active phase of labor, the physical exertion acts as a form of intense exercise, which can cause blood glucose levels to drop. Conversely, the stress hormones released during labor, such as cortisol and adrenaline, can trigger spikes in glucose.
If maternal glucose is not strictly controlled, the fetus is at risk of hyperglycemia, which can lead to neonatal hypoglycemia immediately after birth as the infant’s own insulin production remains high while the maternal glucose source is severed. Historically, managing this balance required frequent finger-stick tests and manual adjustments of insulin drips, often every hour. The introduction of EndoTool IV aims to automate these calculations using a proprietary algorithm that predicts how a patient will respond to insulin based on their unique physiological profile and current glucose trends.
Chronology of Glooko’s Glycemic Management Strategy
The presentation at the DTS meeting represents the latest chapter in Glooko’s multi-year effort to expand its footprint from outpatient data management to comprehensive, inpatient clinical decision support.
- The Acquisition and Integration Phase: Glooko’s journey into the inpatient space was accelerated by its strategic acquisition of technologies designed for hospital-based glycemic management. By integrating these tools into their broader digital ecosystem, Glooko sought to create a "closed-loop" of data that follows the patient from their home to the hospital and back.
- Expansion of the Ambulatory Platform: Prior to the recent data release, Glooko expanded its capabilities with the launch of GestationalCare™. This module was specifically designed for the ambulatory (outpatient) setting, allowing care teams to monitor fasting and post-meal glucose patterns throughout the duration of a pregnancy.
- The DTS Announcement (October 28): The presentation of the EndoTool IV data serves as the clinical validation of the "inpatient" side of this strategy. It demonstrates that the same level of digital precision used in daily life can be successfully applied to the most critical hospital scenarios.
- Future Implementation: Moving forward, Glooko intends to further synchronize the data between GestationalCare™ and EndoTool IV, ensuring that the clinicians in the L&D ward have access to the patient’s entire pregnancy glucose history, thereby allowing for even more informed dosing decisions.
Expert Perspectives and Official Reactions
The medical community has reacted with cautious optimism to the findings. Joseph Aloi, MD, an Endocrine Society member and the section chief of Endocrinology and Metabolism at Advocate Health, Wake Forest University School of Medicine, emphasized the unique pressures of the L&D environment. Dr. Aloi noted that the real-world findings are particularly encouraging because they demonstrated tight glycemic control without a single instance of severe hypoglycemia among the 267 patients evaluated.
"Labor and delivery represents a uniquely dynamic period for glycemic management, when insulin requirements can change quickly," Dr. Aloi stated. He highlighted that personalized dosing is not just a convenience but a safety necessity. The zero-incidence rate of severe hypoglycemia is a benchmark that many hospitals struggle to achieve with manual titration protocols.
Mark Clements, MD, PhD, Glooko’s chief medical and strategy officer, framed the data within the company’s larger vision of "connected care." According to Dr. Clements, the goal is to reduce the fragmentation that often occurs when a patient moves between different care settings. He argued that diabetes management does not end at the hospital door. By providing a continuous thread of data and decision-support tools, Glooko aims to support the patient through the outpatient monitoring of pregnancy, the precision management of labor, and the often-overlooked postpartum transition.
Broader Impact on Healthcare Systems and Patient Outcomes
The implications of these findings extend beyond individual patient safety to the broader operational efficiency of healthcare systems. Managing intravenous insulin is one of the most time-consuming tasks for labor and delivery nurses. Manual protocols require complex calculations and frequent monitoring, which can lead to "alarm fatigue" and an increased risk of medication errors.
By implementing a computerized system like EndoTool IV, hospitals can potentially:
- Improve Nursing Workflow: Automating the calculation of insulin doses reduces the cognitive load on nursing staff, allowing them to focus on other aspects of the birthing process.
- Reduce Length of Stay: Better glycemic control is often correlated with fewer neonatal complications, which can reduce the need for Neonatal Intensive Care Unit (NICU) admissions and shorten the hospital stay for both mother and child.
- Standardize Care: In a large hospital system with 43 facilities, as seen in the study, technology ensures that a patient receives the same high standard of care regardless of which specific ward or shift team is treating them.
Furthermore, the data reinforces the growing trend of "precision medicine" in diabetes care. Rather than relying on sliding-scale insulin protocols—which are increasingly viewed as reactive and outdated—tools like EndoTool IV allow for a proactive approach. The algorithm looks at the rate of change in glucose, not just a single static number, to determine the next dose.
Conclusion and Future Outlook
The data presented by Glooko at the Diabetes Technology Society meeting marks a significant step forward in the validation of digital health tools for specialized populations. As the prevalence of gestational diabetes continues to rise globally—driven by shifting demographics and increasing rates of obesity—the need for scalable, reliable, and safe glucose management tools has never been greater.
The success of EndoTool IV in the labor and delivery ward suggests that the future of diabetes management lies in integrated platforms that connect every phase of the patient journey. For pregnant individuals living with diabetes, the promise of a safer delivery with reduced risk of glycemic extremes is a major clinical advancement. As Glooko continues to refine its GestationalCare™ and EndoTool suites, the medical community will likely look for further studies on how these tools impact long-term postpartum outcomes and neonatal health. For now, the real-world evidence suggests that when it comes to the complex "marathon" of labor, a computerized helping hand may be exactly what clinicians and patients need.
